Comprehensive Codified Algorithms to Identify the Underestimated Burden of Hidradenitis Suppurativa in the United States

被引:0
|
作者
Ingram, John R. [1 ]
Geissbuhler, Yvonne [2 ]
Darcy II, John [3 ]
Foley, Stephen [4 ]
Gaffney, Alex [4 ]
McConnon, Aine [4 ]
Richardson, Craig [2 ]
Garg, Amit [5 ]
机构
[1] Cardiff Univ, Dept Dermatol & Acad Wound Healing, Div Infect & Immun, Cardiff, Wales
[2] Novartis Pharm AG, Basel, Switzerland
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Ireland Ltd, Dublin, Ireland
[5] Northwell Hlth, New Hyde Pk, NY USA
关键词
Hidradenitis suppurativa; HS; Real-world evidence; Algorithm; Diagnosis; Prevalence; Incidence;
D O I
10.1007/s13555-024-01259-0
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionHidradenitis suppurativa (HS) is a painful, inflammatory skin disease associated with a high disease burden and long diagnostic delay. Prevalence estimates of HS vary widely in the literature owing to differing estimation methodologies. This study aimed to apply stepwise algorithms to estimate the prevalence of possible/diagnosed cases of HS in the US.MethodsThis was a retrospective cohort study in adult and pediatric patients with HS which utilized data from four US databases (MarketScan [Medicare and Medicaid] and Optum [electronic health record (EHR) and Clinformatics Data Mart (CDM)]). Patients with possible/diagnosed HS were identified using two algorithms (termed Algorithm 1 and Algorithm 2), which assessed symptoms such as multiple skin boils in site-specific areas based on international classification of disease (ICD) codes. Patients with diagnosed HS were defined as having >= 2 outpatient or >= 1 inpatient diagnosis codes of HS. In each database, patients with continuous medical and pharmacy benefits in the 365 days pre-index and 0-365 days post-index periods were eligible for inclusion.ResultsAcross all databases, Algorithm 2 (MarketScan Medicare [N = 309,916]; MarketScan Medicaid [N = 188,783]; Optum EHR [N = 366,158]; Optum CDM [N = 173,812]) identified more patients with possible/diagnosed HS than Algorithm 1 (MarketScan Medicare [N = 194,353]; MarketScan Medicaid [N = 99,276]; Optum EHR [N = 177,957]; Optum CDM [N = 112,244]). Based on ICD-9/10 codes, the 5-year period prevalence of HS ranged from 0.06% to 0.12% across all databases, while for Algorithm 1 and Algorithm 2, this ranged from 0.27% to 0.41% and 0.49% to 0.78%, respectively. Adults and females generally had a higher 5-year period prevalence versus pediatric patients and males, respectively.ConclusionThis real-world study highlights that HS diagnosis codes alone may be insufficient to estimate the prevalence of HS, demonstrating the value of employing algorithms in practice which assess for parameters such as multiple skin boils in site-specific areas. Integrating robust methods to identify the prevalence of HS may improve the diagnostic delay observed in HS and improve treatment outcomes.
引用
收藏
页码:2859 / 2876
页数:18
相关论文
共 50 条
  • [1] The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis
    Kimball, Alexandra B.
    Sundaram, Murali
    Gauthier, Genevieve
    Guerin, Annie
    Pivneva, Irina
    Singh, Rakesh
    Ganguli, Arijit
    DERMATOLOGY AND THERAPY, 2018, 8 (04) : 557 - 569
  • [2] The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis
    Alexandra B. Kimball
    Murali Sundaram
    Genevieve Gauthier
    Annie Guérin
    Irina Pivneva
    Rakesh Singh
    Arijit Ganguli
    Dermatology and Therapy, 2018, 8 : 557 - 569
  • [3] Inpatient burden of hidradenitis suppurativa in the United States: analysis of the 2016 National Inpatient Sample
    Khanna, Raveena
    Whang, Katherine A.
    Huang, Amy H.
    Williams, Kyle A.
    Khanna, Rayva
    Byrd, Angel S.
    Okoye, Ginette A.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 1150 - 1152
  • [4] Inpatient burden of hidradenitis suppurativa in the United States: Analysis of the 2016 National Inpatient Sample
    Khanna, R.
    Whang, K.
    Byrd, A. S.
    Okoye, G.
    Kwatra, S. G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S34 - S34
  • [5] Characterizing inpatient hospitalizations for hidradenitis suppurativa in the United States
    Anzaldi, Laura
    Perkins, Jamilah A.
    Byrd, Angel S.
    Kharrazi, Hadi
    Okoye, Ginette A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 510 - 513
  • [6] Hidradenitis Suppurativa Prevalence by Age and Race in the United States
    Verma, Kritin K.
    Friedmann, Daniel P.
    Deligonul, Fatma Z.
    Koch, Ryan
    Hurley, Kara K.
    Aldrete, Jonathan
    Tarbox, Michelle B.
    JOURNAL OF DERMATOLOGY & DERMATOLOGIC SURGERY-JDDS, 2024, 28 (02): : 105 - 107
  • [7] Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012
    McMillan, Kathleen
    SKIN APPENDAGE DISORDERS, 2015, 1 (03) : 117 - 122
  • [8] Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States
    Yang, Eric J.
    Beck, Kristen M.
    Bhutani, Tina
    Feldman, Steven R.
    Shi, Vivian Y.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (05) : 519 - 521
  • [9] Association of Low Socioeconomic Status With Hidradenitis Suppurativa in the United States
    Wertenteil, Sara
    Strunk, Andrew
    Garg, Amit
    JAMA DERMATOLOGY, 2018, 154 (09) : 1086 - 1088
  • [10] Completed suicide in patients with hidradenitis suppurativa: A population analysis in the United States
    Garg, A.
    Pomerantz, H.
    Midura, M.
    Papgermanos, V.
    Strunk, A.
    Merson, J.
    Alloo, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S38 - S38